Facebook Facebook Facebook Facebook
Jun 15

Exciting new data on HT-100!

Recently, Akashi Rx published data from their Phase 1b/2a trial of HT-100.  HT-100, also known as halofuginone, is a powerful anti-fibrotic/anti-inflammatory that will help ALL boys with Duchenne, regardless of mutation.  The Little Hercules Foundation is proud to be a financial supporter of this promising therapy.  Read the press release here!

Sign up for Updates

No spam. Just periodic updates on what we are doing and how you can help.